Trivium Point Advisory LLC Invests $1.48 Million in Boston Scientific Corporation $BSX

Trivium Point Advisory LLC bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 34,578 shares of the medical equipment provider’s stock, valued at approximately $1,476,000.

A number of other large investors also recently added to or reduced their stakes in the business. Diamond Hill Capital Management LLC Investment Advisor bought a new position in shares of Boston Scientific during the second quarter valued at about $6,736,000. HBK Sorce Advisory LLC purchased a new stake in Boston Scientific during the 2nd quarter valued at about $402,000. Gould Asset Management LLC CA bought a new position in Boston Scientific during the 2nd quarter worth approximately $445,000. J.Safra Asset Management Corp bought a new stake in Boston Scientific in the second quarter valued at approximately $45,000. Finally, Global Retirement Partners LLC purchased a new position in shares of Boston Scientific in the second quarter worth $1,609,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $51.77 on Monday. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The stock has a market cap of $75.02 billion, a price-to-earnings ratio of 20.96, a PEG ratio of 1.13 and a beta of 0.56. The firm’s 50-day moving average is $46.06 and its 200 day moving average is $59.11. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the business earned $0.75 earnings per share. The company’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has approved a stock buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of analyst reports. BTIG Research decreased their price objective on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, July 29th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Argus reiterated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Zacks Research lowered Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Finally, TD Cowen reduced their target price on Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: An investment analysis argues that Boston Scientific could recover from its recent headwinds, supporting the view that the company’s diversified portfolio and structural-growth markets can reaccelerate over time. Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead
• Positive Sentiment: Analyst consensus remains broadly favorable, with brokerage recommendations suggesting that BSX may merit portfolio consideration. However, the article cautions that sell-side ratings can be overly optimistic and should not be used as the sole investment signal. Brokers Suggest Investing in Boston Scientific
• Neutral Sentiment: Recent fund commentary highlights Boston Scientific’s second-quarter performance and the factors that affected the stock, giving investors additional context on the company’s operating challenges but offering no new company guidance or specific catalyst. Here’s What Hurt Boston Scientific Corporation in Q2
• Negative Sentiment: Parnassus Investments identified a growth slowdown in key Boston Scientific businesses. That raises concerns about near-term revenue momentum and could pressure the stock if weaker growth persists, despite the company’s recent earnings beat and positive longer-term outlook. Boston Scientific Faces Growth Slowdown in Key Businesses

Insider Activity at Boston Scientific

In related news, Director Cheryl Pegus bought 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ? increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Edward J. Ludwig bought 5,000 shares of the firm’s stock in a transaction on Friday, July 31st. The shares were bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 204,322 shares of company stock worth $9,939,221 over the last quarter. 0.34% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.